Conducting a quality study of the medicinal product - Vortioxetine
Phase 1
- Conditions
- o therapeutic indication in the current trial with healthy volunteers. The intended indication is for the treatment of major depressive episodes in adultsTherapeutic area: Diseases [C] - Nervous System Diseases [C10]MedDRA version: 21.1Level: LLTClassification code: 10081270Term: Major depressive disorder Class: 10037175
- Registration Number
- CTIS2023-509946-36-00
- Lead Sponsor
- CCDRD Cooperative Clinical Drug Research and Development AG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method